Back to All Articles
You must be logged in to create a new articleBrowse articles with tag: Generic
All Articles
Patexia Insight 213: The Revlimid Dispute From Antitrust Battles to Patent Litigation
Revlimid (lenalidomide), developed by Celgene Corporation, has been a groundbreaking treatment for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma... Read More
Top 10 Pharmaceuticals Losing Exclusivity in the US in 2024
As the relentless march of time continues, pharmaceutical executives find themselves facing the inevitability of patent expirations and the subsequent... Read More
UroGen Pharma Faces Paragraph IV Challenge as Teva Pursues Generic Jelmyto Approval
Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted... Read More
Pharmaceutical Patents Set to Expire in 2024: Implications and Opportunities
Source: https://www.greyb.com/blog/drug-patents-expiring-2024/ The pharmaceutical industry is undergoing a important phase as numerous patents for key drugs are slated to expire... Read More
Patexia Insight 192: Top Brand and Generic Companies in ANDA 2023
In August, our much-anticipated fourth annual ANDA Litigation Intelligence Report made its entrance into the world of pharmaceutical litigation. This... Read More
Common Pitfalls in ANDA Preparation and How to Avoid Them
When it comes to preparing an Abbreviated New Drug Application (ANDA), there are several common pitfalls that applicants often encounter.... Read More